A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Sequential, Multiple Ascending-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes.

Trial Profile

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Sequential, Multiple Ascending-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Fasiglifam (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Takeda
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Jun 2012 Results published in Clinical Pharmacology and Therapeutics.
    • 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top